Systemic lupus erythematosus: frequency of haematological abnormalities and screening for and causes of psychiatric manifestations

Maria José Leandro

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease involving multiple organs and systems. It is characterized by a relapsing and remitting course with flares of variable severity. It frequently affects young woman of childbearing age. The last decades have seen large advances in the treatment of SLE but it remains a disease associated with considerable morbidity and important mortality. In this issue of the Acta Reumatologica Portuguesa three different articles on SLE are published. The article by Aleem et al. is a report on a retrospective cohort study looking at the frequency of haematological abnormalities and clinical haematological manifestations in patients with SLE both at diagnosis and after a mean follow up of 10 years and their association with other disease manifestations and organ involvement. The two other articles are reviews of the literature focusing on psychiatric manifestations in patients with SLE. Vargas and Vaz present a systematic literature review spanning 10 years of articles investigating methods of screening for probable psychiatric manifestations of SLE: cognitive dysfunction and mood and anxiety disorders. Braga and Campar review the published evidence for biological causes of depression in patients with SLE.

Haematological abnormalities are among the most common abnormalities detected in the assessment of patients with SLE and are associated with significant clinical manifestations. Previous studies have suggested that the frequency of different disease manifestations in SLE can vary in different populations. The article of Aleem et al is a retrospective study of a cohort of more than 600 patients followed up in a University Centre in Riyadh, Saudi Arabia. The same cohort had already been described in previous publications. At diagnosis anaemia, lymphopenia and leukopenia, low complement, positive Coomb’s test, prolonged coagulation time and positive antiphospholipid antibodies were frequently seen. At the last follow up anaemia, lymphopenia and low complement were frequently present. Anaemia was the most common manifestation both at diagnosis and at last follow up. Differences with frequencies reported for other cohorts from other countries are at least partially due to what types of anaemia were included. The authors found different associations between the haematological abnormalities and other disease manifestations but it is unclear to what extent this is useful in guiding monitoring and treatment of SLE patients.

Mild to moderate anaemia is very frequently present in patients with SLE and can contribute to other symptoms such as fatigue. In clinical practice, the anaemia is often multifactorial with causes including the active disease itself, direct and indirect effects of drugs and associated conditions. It is not always easy to diagnose the exact contribution of each of these factors and treat appropriately. In patients with chronic anaemia it can also be difficult to decide when to reinvestigate for contributing factors that can be treated.

Psychiatric manifestations in patients with SLE are common including early in the course of the disease. They are associated with lower quality of life, increased functional disability, sleep disorders, increased unemployment rate and health service utilization. They also contribute to non-adherence to treatment. These manifestations are frequently undiagnosed and undertreated. This is partially due to uncertainty about its exact cause, i.e., whether they reflect active immune mechanisms and central nervous system pathology or the psychosocial impact of a chronic disease, and to...
difficulty in diagnosis. Difficulty in diagnosis is related
to the nature of the complaints and lack of easy to use,
validated tools for screening or diagnosis particularly
by physicians who are not mental health specialists.
There is a wide variation in the prevalence of psychi-
atric manifestations reported in different cohort stu-
dies and this is at least partially due to variability in
the tools used for diagnosis and different criteria. Re-
cently published reviews provide an overview of neu-
ropsychiatric manifestations in patients with SLE and
its pathogenesis, its treatment and of the role of mo-
dern neuroimaging in its diagnosis.7,8,9

Vargas and Vaz present a systematic review of arti-
cles published between 2002 and 2012 that reported
on the use of a screening tool or method to diagnose
cognitive dysfunction, mood or anxiety disorders in
patients with SLE. Once their inclusion and exclusion
criteria were applied only 12 articles were selected for
detailed analysis. In the studies reviewed, different
tools and methods were used for screening SLE pa-
tients (both adults and paediatric populations) for
these psychiatric manifestations, the majority of them
not specifically developed for SLE. The tools included
physician-administered and self-administered tools
with variable sensitivities, specificities, positive and
negative predictive values. The review emphasizes the
need for further research into this area, including the
need for validated translations of tools based on the
English language so that they can be used in other po-
culations.

Depressive symptoms in patients with SLE are very
commonly observed. It is always difficult to assess
whether they are a consequence of the psychosocial
impact of the disease or related to dysfunction of the
central nervous system directly related to the disease
process. In the absence of evidence of active disease in
other organs or systems it is generally treated sympto-
matically and not with immunosuppressive drugs.

Braga and Campar reviewed published studies that
explore possible biologic causes for depression in SLE
including human and animal studies. The roles of
chronic inflammation and persistently raised cytokine
levels, dysfunction of the hypothalamic-pituitary-
adrenal axis associated with immune dysfunction and
possible direct and indirect effects of neuro-reactive
antibodies as well as corticoterapy and cerebro-vascular
disease are reviewed.

The two review articles focusing on psychiatric
manifestations in SLE emphasise its high frequency
and underdiagnosis and undertreatment. Data re-
viewed shows the uncertainty regarding the etiology of
these manifestations in patients with SLE and the dif-

culty in its diagnosis and treatment. It is also often dif-
ficult to distinguish neuropsychiatric manifestations
of SLE from other neuropsychiatric conditions with
different etiologies. There is a clear need for further re-
search in these areas to expand our knowledge of spe-
cific pathogenic mechanisms involved, development of
reliable diagnostic tools and possible specific thera-
peutic agents. Routine clinical practice when looking
after patients with SLE should include easy access to a
multidisciplinary team that includes a neurologists, a
psychiatrist and other specialists in mental health.

CORRESPONDENCE TO
Maria José Leandro
Centre for Rheumatology Research,
Department of Medicine, UCL
Rayne Building, Room 416
5 University Street
London WC1E 6JF
United Kingdom
E-mail: maria.leandro@ucl.ac.uk

REFERENCES
1. Aleem A, Arfaj AA, Khalil N, Alarfaj H. Haematological abnormali-
ties in systemic lupus erythematosus. Acta Reumatol Port 2014;39:
236-241.
2. Vargas JV, Vaz CJ. Evaluation of central nervous system involve-
ment in SLE patients. Screening psychiatric manifestations – a sys-
3. Braga,J, Campar A. Causas biológicas de depressão em doentes com
Lupus Eritematoso Sistémico: um estudo de revisão. Acta Reuma-
4. Arfaj AA and Khalil N. Clinical and immunological manifestations
5. Hopkinson ND, Doherty M, Powell RJ. Clinical features and race-
-specific incidence/prevalence rates of systemic lupus erythema-
tosus in a geographically complete cohort of patients. Annals of the
Rheumatic Diseases 1994; 53: 675-680
HM, Fessler BJ and Reveille JD. Early clinical manifestations, disease
activity and damage of systemic lupus erythematosus among two dis-
tinct US Hispanic subpopulations. Rheumatology 2004; 43. 358-363
7. Jeltsch-David H, Muller S. Neuropsychiatric systemic lupus ery-
thematosus: pathogenesis and biomarkers. Nature Reviews Neu-ology 2014 online publication 9 September
S. Depression and systemic lupus erythematosus: a systematic re-
9. Zardi EM, Taccone A, Mariogliano B, Margiotta DP, Alelra A. Neu-
ropsychiatric systemic lupus erythematosus: tools for the diagno-
sis. Autoimmune Reviews 2014; 13: 831-839
10. Hanly JG. Diagnosis and management of neuropsychiatric SLE. Nat
11. Marenjo MF, Walmann CA, de Achaval S, Zhang H, Garcia-Gon-
zalez A, Richardson MN, Reveille JD, Suarez-Almazor ME. Mea-
suring therapeutic adherence in systemic lupus erythematosus with